Cardiovascular Systems, Inc. (CSII)
(Delayed Data from NSDQ)
$39.49 USD
+1.98 (5.28%)
Updated May 3, 2019 04:00 PM ET
After-Market: $39.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.49 USD
+1.98 (5.28%)
Updated May 3, 2019 04:00 PM ET
After-Market: $39.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cardiovascular Systems Rides on Launches Amid Coronavirus Woes
by Zacks Equity Research
Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.
Cardiovascular Systems (CSII) Up 9.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected (Revised)
by Zacks Equity Research
Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.
Cardiovascular Systems (CSII) Misses Q4 Earnings Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q2 earnings as patients avoid hospitals.
Cardiovascular Systems (CSII) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 2.27% and 10.49%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cardiovascular Systems (CSII) Q4 Earnings Expected to Decline
by Zacks Equity Research
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin
by Zacks Equity Research
Cardiovascular Systems (CSII) witnesses a significant decline in procedure volumes in Q3 for patients treated with orbital atherectomy devices.
Cardiovascular Systems (CSII) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 11.11% and -4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cardiovascular Systems (CSII) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Cardiovascular Systems (CSII) Down 10.8% Since Last Earnings Report?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems Grows on Domestic Sales Amid Margin Woe
by Zacks Equity Research
Cardiovascular Systems (CSII) continues to register solid top-line growth on strength in the domestic atherectomy businesses.
Steer Clear Of These 5 Toxic Stocks Before It's Too Late
by Zacks Equity Research
Figuring out bloated toxic stocks on a consistent basis and discarding them at the right time is the key to successful investing.
Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q2
by Zacks Equity Research
We are upbeat about Cardiovascular Systems' (CSII) year-over-year uptick in global Coronary and peripheral device revenues during Q2.
Cardiovascular Systems (CSII) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -233.33% and 0.65%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cardiovascular Systems (CSII) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiovascular Systems (CSII) Stock Hits New 52-Week High
by Zacks Equity Research
Cardiovascular Systems (CSII) is optimistic about maintaining its growth momentum on several recent developments.
Cardiovascular Systems Sees Peripheral OAS Micro Crown Success
by Zacks Equity Research
This is a major achievement for Cardiovascular Systems (CSII) toward strengthening its portfolio for the treatment of CLI.
Cardiovascular Systems (CSII) Up 6.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q1
by Zacks Equity Research
We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -88.89% and 0.72%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Is Cardiovascular Systems (CSII) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems Set to Present LIBERTY 360 Outcome
by Zacks Equity Research
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).
Cardiovascular Systems (CSII) Earnings Match Estimates in Q4
by Zacks Equity Research
We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
Cardiovascular Systems (CSII) Meets Q4 Earnings Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 0.00% and 3.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cardiovascular Systems (CSII) Q4 Earnings Expected to Decline
by Zacks Equity Research
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.